EURneffy®, described by Anaphylaxis UK as the country's first needle-free adrenaline nasal spray, became available on prescription for people with serious allergies on 24 October 20251. The announcement was made by Allergy UK incorporating Anaphylaxis UK, which said the treatment is an additional licensed option for the emergency treatment of anaphylaxis1.
Each single-use spray contains 2mg of adrenaline and is designed for adults and children who weigh 30kg or more1. At the first sign of anaphylaxis, the user inserts the nozzle into one nostril and presses the plunger to release the full dose; the adrenaline is absorbed through the nasal lining and enters the bloodstream quickly, even if the nose is congested from hay fever or other allergies1. Anaphylaxis UK states that clinical studies and real-world data show the spray delivers adrenaline just as effectively as an injection, and that it can also be administered to unconscious patients because it does not require inhalation1.
The spray is a prescription-only medicine1. Anaphylaxis UK said it may take some time for all GP practices to be able to prescribe EURneffy®, and that this will vary between clinics, with plans in place to make it accessible to everyone as soon as possible1. It said some people may choose to switch from an adrenaline auto-injector after discussing it with their GP or allergy specialist, while others may prefer to keep using auto-injectors; carrying both is not a requirement, and patients should follow their clinician's advice and always carry two doses of adrenaline1.
Allergy UK lists the adrenaline options currently available on prescription in the UK as adrenaline auto-injectors (AAIs) such as EpiPen and Jext, and intranasal adrenaline, EURneffy2. It states that a second dose may be needed if symptoms do not improve after five minutes or get worse, and that two in-date forms of prescribed adrenaline should be carried at all times2.
"Anaphylaxis is a serious and life-threatening allergic reaction that can happen within minutes of exposure to an allergen, such as foods, insect stings, or certain medications. Adrenaline is the first-line treatment and giving it quickly is crucial to prevent serious complications."
Why it matters for households
Anaphylaxis UK describes anaphylaxis as a serious and life-threatening allergic reaction that can happen within minutes of exposure to an allergen such as foods, insect stings or certain medications1. Allergy UK advises that anyone experiencing a serious reaction or anaphylaxis should call 999 immediately, and that a severe allergic reaction must be treated with adrenaline2. It lists the ABC symptoms as airway swelling (throat, tongue or upper airways, hoarse voice, difficulty swallowing), breathing difficulty (sudden wheezing, noisy breathing, persistent cough) and circulation problems (dizziness, feeling faint, sudden sleepiness, confusion, pale clammy skin, loss of consciousness or collapse)2. It advises not to wait to see how bad a reaction is, and that if in doubt the adrenaline should be used2.
For households managing a serious allergy, the change is that a needle-free device is now among the options a GP or allergy specialist can prescribe, alongside auto-injectors1. Anaphylaxis UK advises anyone interested in the needle-free option to speak to their GP, and notes that availability will vary between practices for a time1. Allergy UK states that a healthcare professional can show patients how to use their specific device, and that guidance, training materials and practice devices are available through manufacturer websites2. After an anaphylactic reaction, Allergy UK says hospital observation is usually for 6 to 12 hours because symptoms can occasionally return2.
What happens next
Anaphylaxis UK said plans are in place to make EURneffy® accessible to everyone as soon as possible, but did not give a date for when prescribing will be available at all GP practices1. No launch price for the UK has been reported.
Households can find general guidance on severe allergic reactions and emergency action in the site's health emergencies hub.
